PubRank

U Germing

Author PubWeight™ 65.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004 1.90
2 The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008 1.89
3 High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia 2005 1.72
4 Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 2013 1.71
5 A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma 2007 1.58
6 Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005 1.57
7 Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012 1.57
8 Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2010 1.48
9 Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992 1.45
10 Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leuk Res 2000 1.42
11 Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy 2004 1.41
12 Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013 1.39
13 Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013 1.37
14 Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001 1.30
15 A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004 1.28
16 Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol 2010 1.26
17 Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013 1.23
18 The 5q- syndrome. Hematology 2004 1.23
19 Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2009 1.22
20 Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007 1.20
21 Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 2012 1.07
22 Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005 1.04
23 The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006 1.04
24 Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol 2002 1.00
25 Acute basophilic leukemia. Eur J Haematol 2001 0.97
26 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2009 0.96
27 Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 2011 0.96
28 Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia 2013 0.95
29 [Imaging of supradiaphragmatic manifestations of extranodal non-Hodgkin's lymphoma]. Radiologe 2002 0.95
30 Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? Leukemia 2013 0.94
31 A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010 0.94
32 Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia 2007 0.93
33 The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia 2003 0.92
34 Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia 2012 0.90
35 The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia 2006 0.89
36 Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013 0.89
37 Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res 2001 0.86
38 Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 1998 0.85
39 Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol 2005 0.84
40 Acute promyelocytic leukemia and pregnancy. Eur J Haematol 2000 0.84
41 Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score. Leukemia 1994 0.83
42 Clonal relationship between langerhans cell histiocytosis and myeloid sarcoma. Leukemia 2012 0.83
43 [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. Beitr Infusionsther 1992 0.83
44 Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol 2005 0.83
45 Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia 2011 0.82
46 Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002 0.81
47 Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002 0.81
48 Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma. Ann Hematol 1999 0.81
49 The German competence network 'Acute and chronic leukemias'. Leukemia 2004 0.81
50 Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol 2004 0.79
51 Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002 0.79
52 Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002 0.79
53 Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia 2005 0.79
54 MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l. Ann Hematol 2007 0.78
55 Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 2003 0.77
56 [Dynamic contrast-enhanced MRI for evaluating bone marrow microcirculation in malignant hematological diseases before and after thalidomide therapy]. Radiologe 2002 0.77
57 Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol Rep 2000 0.77
58 Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010 0.77
59 Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts. Leukemia 2013 0.77
60 Patient-controlled versus staff-controlled analgesia with pethidine after allogeneic bone marrow transplantation. Pain 1998 0.77
61 Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis. Br J Haematol 2000 0.76
62 Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals. Infection 2013 0.76
63 Improving the prognostic evaluation of patients with lower risk myelodysplastic syndromes. Leukemia 2008 0.76
64 Prevention of postsplenectomy sepsis. Hematol J 2001 0.75
65 Acute acalculous cholecystitis complicating oral recontamination after allogeneic bone marrow transplantation. Oncol Rep 2011 0.75
66 [Splenomegaly and portal hypertension of unusual etiology in a 62-year-old patient]. Internist (Berl) 1996 0.75
67 Testicular infiltration in acute myeloid leukemia with complex karyotype including t(8;21). Ann Hematol 2001 0.75
68 [Bone marrow involvement in hematologic neoplasms and solid tumors]. Radiologe 2000 0.75
69 Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator. Thromb Haemost 1997 0.75
70 Fatal hyperleukocytic syndrome in a patient with chronic myelomonocytic leukemia. Leuk Res 1997 0.75
71 The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22). Leukemia 2007 0.75
72 Pleural carcinosis confirmed by adjuvant cytological methods: a case report. Diagn Cytopathol 1998 0.75
73 [Myelodysplastic syndromes]. Internist (Berl) 1998 0.75
74 Expression of cd34 and p-glycoprotein - prognostic-significance in primary myelodysplastic syndromes. Int J Oncol 1995 0.75
75 Pseudomonas aeruginosa orbital phlegmon in a patient treated for myelodysplastic syndrome with concomitant Sjögren's syndrome. Eur J Med Res 1999 0.75
76 Primary pancreatic lymphoma--a rare cause of cholestasis leading to surgical treatment. Ann Hematol 2006 0.75
77 [Aspects of internal medicine]. Radiologe 2000 0.75
78 Serum deoxythymidine kinase in myelodysplastic syndromes. Cancer 1994 0.75
79 [Splenectomy for thrombocytopenic purpura. Retrospective analysis of the postoperative course]. Chirurg 2005 0.75
80 [Vaccination after splenectomy and in asplenia]. Internist (Berl) 1998 0.75
81 [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome]. Dtsch Med Wochenschr 1996 0.75
82 Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide. Leuk Res 2005 0.75
83 Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia. Leukemia 2006 0.75
84 The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma 2005 0.75
85 Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance. Leuk Lymphoma 1998 0.75
86 Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis. Ann Hematol 2013 0.75
87 [Myelodysplastic syndromes. The epidemiological and etiological aspects]. Dtsch Med Wochenschr 1992 0.75
88 An unusual presentation of a common infection. Infection 2012 0.75
89 Severe musculoskeletal pain after cyclosporin A treatment in a patient undergoing allogeneic BMT. Oncol Rep 1996 0.75
90 [Myelodysplastic syndromes]. Internist (Berl) 2010 0.75
91 [Role of aggressive treatment strategies for myelodysplastic syndromes]. Praxis (Bern 1994) 1999 0.75
92 Massive extramedullary disease progression in a patient with stable multiple myeloma during G-CSF priming for peripheral blood progenitor mobilization. Oncol Rep 1999 0.75
93 Improved prophylaxis against overwhelming postsplenectomy infections. Eur J Haematol 1997 0.75
94 [Dynamic MRI of the lumbar spine for the evaluation of microcirculation during anti-angiogenetic therapy in patients with myelodysplastic syndromes]. Rofo 2002 0.75